Videos

Patients with rheumatoid arthritis who had inadequate response to previous biologic disease-modifying antirheumatic drugs found greater pain relief when taking 2 mg or 4 mg of baricitinib compared with placebo.

Eric M. Ruderman, MD, addresses adverse events and toxicities in patients taking disease-modifying antirheumatic drugs (DMARDs).

The orthopedic surgeron from Northwell Health discussed the expectations of physically active older patients undergoing care for joints and knees.

Patients in tocilizumab treatment group 4 times more likely to see remission.

John Stone, MD, Massachusetts General Hospital, discussed study results and fear surrounding giant cell arteritis.

When patients leave the waiting room of their provider, their concerns can go with them. With the help of social media channels like Facebook and Twitter, those concerns can be addressed while information is shared in a new and effective manner.

Nancy Lane, MD, discussed her team's study on abaloparatide, a new preparation of a hormone, and how it can stimulate bone formation.